314 related articles for article (PubMed ID: 18201579)
1. Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Zerilli T; Pyon EY
Clin Ther; 2007 Dec; 29(12):2614-34. PubMed ID: 18201579
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
3. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Mikhail N
Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
[TBL] [Abstract][Full Text] [Related]
4. Managed care perspective on three new agents for type 2 diabetes.
VanDeKoppel S; Choe HM; Sweet BV
J Manag Care Pharm; 2008 May; 14(4):363-80. PubMed ID: 18500914
[TBL] [Abstract][Full Text] [Related]
5. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes.
Gallwitz B
Drugs Today (Barc); 2007 Oct; 43(10):681-9. PubMed ID: 17987221
[TBL] [Abstract][Full Text] [Related]
6. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Scheen AJ
Diabetes Metab; 2012 Apr; 38(2):89-101. PubMed ID: 22197148
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Charbonnel B; Karasik A; Liu J; Wu M; Meininger G;
Diabetes Care; 2006 Dec; 29(12):2638-43. PubMed ID: 17130197
[TBL] [Abstract][Full Text] [Related]
8. Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update).
Gallwitz B
Drugs Today (Barc); 2007 Nov; 43(11):801-14. PubMed ID: 18174966
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Rhee EJ; Lee WY; Min KW; Shivane VK; Sosale AR; Jang HC; Chung CH; Nam-Goong IS; Kim JA; Kim SW;
Diabetes Obes Metab; 2013 Jun; 15(6):523-30. PubMed ID: 23320436
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
11. Sitagliptin.
Lyseng-Williamson KA
Drugs; 2007; 67(4):587-97. PubMed ID: 17352516
[TBL] [Abstract][Full Text] [Related]
12. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.
Ahrén B
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):487-98. PubMed ID: 19748066
[TBL] [Abstract][Full Text] [Related]
13. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.
Gallwitz B
Drugs Today (Barc); 2007 Jan; 43(1):13-25. PubMed ID: 17315049
[TBL] [Abstract][Full Text] [Related]
14. New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin.
Gagliardino JJ; Santoro S; Arellano S; Di Girolamo G
Expert Opin Pharmacother; 2008 Jun; 9(9):1495-507. PubMed ID: 18518780
[TBL] [Abstract][Full Text] [Related]
15. Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.
Aaboe K; Akram S; Deacon CF; Holst JJ; Madsbad S; Krarup T
Diabetes Obes Metab; 2015 Jan; 17(1):74-81. PubMed ID: 25243647
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
[TBL] [Abstract][Full Text] [Related]
17. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
Garg SK; Moser EG; Bode BW; Klaff LJ; Hiatt WR; Beatson C; Snell-Bergeon JK
Endocr Pract; 2013; 19(1):19-28. PubMed ID: 23186950
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
Mikhail N
Vasc Health Risk Manag; 2008; 4(6):1221-7. PubMed ID: 19337535
[TBL] [Abstract][Full Text] [Related]
19. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
20. Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.
Plosker GL
Drugs; 2014 Feb; 74(2):223-42. PubMed ID: 24407560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
